Psyched: DMT & SSRIs For Depression, MDMA Training, Negative Responses To Psychedelics & More

Depression Relief: Possible Therapy Boost With DMT & SSRIs Small Pharma Clinical Results

New findings on safety, tolerability and efficacy from a clinical study assessing the interaction of psychedelics and traditional pharma for the treatment of major depressive disorder (MDD) are out.

They correspond to U.K.’s short-acting psychedelic therapies developer Small Pharma’s DMTTF open-label Phase 1b study assessing the joint work of its “native” DMT compound, SPL026 and selective serotonin reuptake inhibitors (SSRIs.) Read more HERE.

Canadian Practitioners Can Now Enroll In MDMA-Assisted Psychotherapy Training Program, Legal Medical Psilocybin Access For Veteran Approved

Canadian not-for-profit organization TheraPsil has received board approval to launch its training program on MDMA-assisted psychotherapy for trauma survivors. TheraPsil has been advancing legal access to psychedelic-assisted psychotherapy since 2019.

The new course, which joins the “Fundamentals of Psilocybin-Assisted Psychotherapy” programs that have already trained 500+ healthcare professionals, extends the nonprofit's advocacy efforts toward including both psilocybin and MDMA for patients in medical need through the country’s Special Access Program (SAP.) Find out more HERE.

Meanwhile, the SAP has authorized a physician to provide Apex Labs’ psilocybin macrodose drug protocol to patient Kelsi Sheren, a Canadian veteran, as therapy for her Treatment Resistant Depression (TRD) within PTSD starting October 2023.

APEX-90 consists of a psilocybin drug product paired with psychotherapy as per Apex’s SUMMIT-90 clinical trial protocol; specifically, following an Investigator Brochure (IB) and Therapy Manual (TM) pertaining to the protocol of the company’s Health Canada-approved 160-patient Phase 2b clinical trial. Continue reading HERE.

Analyzing Long-Term Negative Responses To Psychedelics: Researchers Release Study

The journal Nature published a new research analysis from Imperial College London (ICL)’s Center for Psychedelic Research and University of California San Francisco (UCSF)’s Psychedelics Division, including renowned David Erritzoe and Robin Carhart-Harris. The study looks at cases where there have been long-term negative psychological responses to psychedelics.

The study was motivated by an alleged ongoing research and reporting bias on positive over negative outcomes with these compounds. Also, they say, “unpleasant acute psychological experiences under psychedelics are not rare—even in research environments” with one study reporting around 40% prevalence of moderate to severe anxiety, panic or distress with high-dose psilocybin in healthy volunteers. Continue reading HERE.

The Milestone Round

Cybin and Fluence partner to support EMBARK training for Phase 3 CYB003 trial for depression.
PharmaTher PHRRF is 'one step closer to being a ketamine leader' due to FDA acceptance.
Defense Dept. grants $1M to Yale & Transcend Therapeutics to study PTSD therapy.
Maine City moves unanimously on decriminalizing psychedelics: Focus on public health.
PsychMD's nationwide, safe-supplied AI-driven ketamine therapy with US Vets in mind.
Exclusive insights: How tech leaders are finding balance through microdosing psychedelics.
Microdosing unveiled: Expert's take on the practice's ups & downs.
Should I tell my doctor if I take psychedelic mushrooms? Most people don't, but...
From fast-acting hemp extracts to Wiz Khalifa mushroom kits: Tracking progressive trends in cannabis & psychedelics.
The psychedelic shift: Advocates' role in reshaping societal views and policies.
Can psychedelic therapy enhance quality of life in seniors?

Psychedelics ETF Weekly Performance

AdvisorShares Psychedelics ETF PSIL opened Monday, Sept. 25 at $1.68, following a consistent slow downtrend as of Monday 18 ($1.70), Monday 11 ($1.75), and Tuesday 5 ($1.79).

On Friday 29, it closed at $1.61, also below prior weeks’ closings ($1.66, $1.74 and $1.78, respectively.)

Week’s highest was $1.76 on Tuesday, Sept. 26, higher than the prior week’s ($1.74) and closer to past highest points $1.77 and $1.8.

Week’s lowest was $1.61, where it stood practically the whole Friday and finally closed (vs. past weeks’ lowest at $1.62, $1.71 and $1.73, respectively.)

The ETF’s yearly price range has again been changed, now set between $3.24 and $1.60 (last week’s bottom was $1.62.)

Highest Trading Psychedelics Stocks Friday, Sept. 29 At Close

GH Research GHRS closed at $10.05, lower than prior Fridays’ closings at $10.33 and $10.50, yet still up from Friday 8’s at $10.00.
COMPASS Pathways CMPS closed at $7.40, down from the prior week’s closing at $7.87 and certainly so from three prior consecutive closings at $9.41.
Mind Medicine (MindMed) MNMD closed at $3.13, also down from past weeks’ closings at $3.62, $4.17, $4.00 and $4.09, respectively.
Enveric Biosciences ENVB closed at $2.38, almost the same as prior Friday’s closing and an uptake from prior weeks’ at $2.28, $2.22 and $2.12.
Bright Minds Biosciences DRUG closed at $1.6, showing a mixed trend: down from past Friday's closing of $1.73 yet still higher than the prior Friday's ($1.57,) down from Friday 8’s at $1.92.
Silo Pharma SILO closed at $1.67, lower than Friday 22’s close at $1.79 and confirming the descending weekly trend (prior closings at $1.85 and $1.98.)
Atai Life Sciences ATAI closed at $1.29, almost the same as Friday 22’s closing price $1.30 and also down from past weeks’ closings ($1.45 and $1.43.)
FSD Pharma HUGE closed at $1.21, slightly under Friday 22’s close at $1.26 and also down from former closings ($1.5 and $1.23.)
Incannex Healthcare IXHL closed at $1.14, down from past Fridays’ closings at $1.18, $1.40 and $1.33, respectively.
Lucy Scientific Discovery LSDI closed at $0.60, slightly under past Fridays’ closings at $0.69, $0.65 and $0.72.
Cybin Inc. CYBN closed at $0.53, almost consistent with the prior Friday’s close and sustaining the upward trend as of Fridays 15 and 8 (closings at $0.33.)